Sumitomo Pharma America (SMPA) is focused on delivering therapeutic and scientific breakthroughs in the areas if critical patient need spanning psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies. The company’s diverse portfolio includes several marketed products and a robust pipeline of early- to late-stage assets.